Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.

Martins AF, Martins JM, do Vale S, Dias T, Silveira C, da Silva IR, Carmo-Fonseca M.

Hormones (Athens). 2016 Jul;15(3):435-440. doi: 10.14310/horm.2002.1691.

2.

Three siblings with familial non-medullary thyroid carcinoma: a case series.

Rashid MO, Haq N, Farooq S, Kiran Z, Siddique S, Pervez S, Islam N.

J Med Case Rep. 2016 Aug 2;10:213. doi: 10.1186/s13256-016-0995-3.

3.

Multiple Endocrine Neoplasia Syndromes: A Comprehensive Imaging Review.

Grajo JR, Paspulati RM, Sahani DV, Kambadakone A.

Radiol Clin North Am. 2016 May;54(3):441-51. doi: 10.1016/j.rcl.2015.12.001. Epub 2016 Mar 10. Review.

PMID:
27153782
4.

Medullary thyroid carcinoma: a review on ethical considerations in treatment of children.

Nozhat Z, Hedayati M.

J Pediatr Endocrinol Metab. 2016 Jun 1;29(6):633-9. doi: 10.1515/jpem-2015-0309. Review.

PMID:
26974132
5.

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Romei C, Ciampi R, Elisei R.

Nat Rev Endocrinol. 2016 Apr;12(4):192-202. doi: 10.1038/nrendo.2016.11. Epub 2016 Feb 12. Review.

PMID:
26868437
6.

Management of hereditary medullary thyroid carcinoma.

Pappa T, Alevizaki M.

Endocrine. 2016 Jul;53(1):7-17. doi: 10.1007/s12020-016-0873-1. Epub 2016 Feb 2. Review.

PMID:
26839093
7.

Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.

Kihara M, Miyauchi A, Yoshioka K, Oda H, Nakayama A, Sasai H, Yabuta T, Masuoka H, Higashiyama T, Fukushima M, Ito Y, Kobayashi K, Miya A.

Auris Nasus Larynx. 2016 Oct;43(5):551-5. doi: 10.1016/j.anl.2015.12.016. Epub 2016 Feb 1.

PMID:
26837867
8.

Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.

Aydoğan Bİ, Yüksel B, Tuna MM, Navdar Başaran M, Akkurt Kocaeli A, Ertörer ME, Aydın K, Güldiken S, Şimşek Y, Cihan Karaca Z, Yılmaz M, Aktürk M, Anaforoğlu İ, Kebapçı N, Duran C, Taşlıpınar A, Kulaksızoğlu M, Gürsoy A, Dağdelen S, Erdoğan MF.

J Clin Res Pediatr Endocrinol. 2016 Mar 5;8(1):13-20. doi: 10.4274/jcrpe.2219. Epub 2015 Dec 18.

9.

Surgery for lymph node metastases of medullary thyroid carcinoma: A review.

Jin LX, Moley JF.

Cancer. 2016 Feb 1;122(3):358-66. doi: 10.1002/cncr.29761. Epub 2015 Nov 5. Review.

10.

Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.

Frank-Raue K, Raue F.

Recent Results Cancer Res. 2015;204:139-56. doi: 10.1007/978-3-319-22542-5_6. Review.

PMID:
26494387
11.

RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.

Qi XP, Zhao JQ, Chen ZG, Cao JL, Du J, Liu NF, Li F, Sheng M, Fu E, Guo J, Jia H, Zhang YM, Ma JM.

Oncotarget. 2015 Oct 20;6(32):33993-4003. doi: 10.18632/oncotarget.4992.

12.

C-Cells and their Associated Lesions and Conditions: A Pathologists Perspective.

Baloch ZW, LiVolsi VA.

Turk Patoloji Derg. 2015;31 Suppl 1:60-79. doi: 10.5146/tjpath.2015.01315. Review.

13.

Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.

Chernock RD, Hagemann IS.

Am J Clin Pathol. 2015 Jun;143(6):768-77. doi: 10.1309/AJCPHWACTTUYJ7DD. Review.

PMID:
25972318
14.

The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.

Colombo C, Minna E, Rizzetti MG, Romeo P, Lecis D, Persani L, Mondellini P, Pierotti MA, Greco A, Fugazzola L, Borrello MG.

Orphanet J Rare Dis. 2015 Mar 1;10:25. doi: 10.1186/s13023-015-0231-z.

15.

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma.

Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335. Review.

16.

Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.

Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, Al-Nahhas A.

Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24. doi: 10.1967/s002449910163. Epub 2015 Feb 13.

17.

Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades.

Sarika HL, Papathoma A, Garofalaki M, Saltiki K, Pappa T, Pazaitou-Panayiotou K, Anastasiou E, Alevizaki M.

Eur J Endocrinol. 2015 Apr;172(4):501-9. doi: 10.1530/EJE-14-0817. Epub 2015 Jan 26.

18.

Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.

Basaran MN, Tuna MM, Karakılıç E, Doğan BA, İmga NN, Berker D, Güler S.

J Endocrinol Invest. 2015 May;38(5):541-6. doi: 10.1007/s40618-014-0224-0. Epub 2014 Dec 12.

PMID:
25501606
19.

Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?

Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R.

Clin Endocrinol (Oxf). 2015 Jun;82(6):892-9. doi: 10.1111/cen.12686. Epub 2014 Dec 29.

PMID:
25440022
20.

A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma.

Kwon H, Kim WG, Choi YM, Jang EK, Jeon MJ, Song DE, Baek JH, Ryu JS, Hong SJ, Kim TY, Kim WB, Shong YK.

Clin Endocrinol (Oxf). 2015 Apr;82(4):598-603. doi: 10.1111/cen.12562. Epub 2014 Sep 1.

PMID:
25041034

Supplemental Content

Loading ...
Support Center